GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Glaukos
What is the history of Glaukos?
Glaukos Corporation has revolutionized ophthalmic care, especially for glaucoma, through its pioneering Micro-Invasive Glaucoma Surgery (MIGS). Launched commercially in 2012, MIGS provided a less invasive option than traditional treatments.
Founded in 1998, Glaukos aimed to lessen the impact of glaucoma by advancing medical devices and therapies. Their initial goal was to offer innovative MIGS treatments that enhance patient results and lower healthcare expenses.
The company has grown significantly, now focusing on glaucoma, corneal health, and retinal diseases. Projected net sales for 2025 are between $475 million and $485 million, a notable increase from $383.5 million in 2024. This growth highlights their strong market presence and ongoing development in managing chronic eye conditions. Discover more about their journey and innovations, including the Glaukos BCG Matrix.
What is the Glaukos Founding Story?
The Glaukos company history began in 1998, with its origins in Southern California. The company was established to address the limitations of existing glaucoma treatments, aiming to pioneer micro-invasive glaucoma surgery (MIGS) as a novel approach.
The Genesis of Glaukos
Glaukos Corporation was founded in 1998, driven by a clear need for improved glaucoma treatments. The company's early vision focused on developing micro-invasive glaucoma surgery (MIGS) to offer more effective and compliant solutions than traditional methods.
- Founded in 1998 in Southern California.
- Addressed limitations in existing glaucoma treatments.
- Pioneered micro-invasive glaucoma surgery (MIGS).
- Focused on improving patient compliance and treatment efficacy.
The Glaukos origin story is deeply intertwined with the innovative work of key figures. UCI Emeritus Professor Richard Hill, a specialist in challenging glaucoma cases, was instrumental as a seminal inventor of Glaukos' first MIGS device. This groundbreaking invention, a small implant designed to restore fluid drainage within the eye, became the foundational technology for the company. Other key founding team members included Dr. Richard L. Lindstrom, Dr. M. Humayun, and Dr. Yossi Mandel, contributing their expertise to the company's early development.
The Glaukos corporation timeline saw a significant milestone in 2002 when the company secured its initial venture capital funding. Versant Ventures led this Series A round, providing $10.0 million. This crucial investment fueled the company's research and development efforts, enabling them to advance their pioneering MIGS technology and bring it closer to market. This early financial backing was vital for the Glaukos company's early development and its subsequent impact on glaucoma treatment.
The development of the Glaukos iStent history is a testament to the company's commitment to innovation. This first-generation MIGS device was designed to be implanted through a minimally invasive procedure, offering a new paradigm for managing intraocular pressure in glaucoma patients. The success of this initial technology paved the way for further advancements and solidified the company's position in the ophthalmic surgical market. Understanding the Revenue Streams & Business Model of Glaukos provides further insight into their strategic growth following these foundational steps.
Complete Glaukos Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
What Drove the Early Growth of Glaukos?
The Glaukos company history is rooted in innovation within the glaucoma treatment sector. Its early development focused on pioneering Micro-Invasive Glaucoma Surgery (MIGS) technology, setting the stage for significant advancements in patient care.
Pioneering MIGS Technology
Glaukos' origin story began with the development of the first trabecular micro-bypass glaucoma stent in 1999. This was followed by the first human implant of this groundbreaking stent in 2001, marking a crucial step in the Glaukos corporation timeline.
FDA Approval and Market Launch
A pivotal moment in the Glaukos company history was the U.S. FDA approval of the iStent Trabecular Micro-Bypass on June 25, 2012. This marked the first ab interno glaucoma implant approved in the United States, revolutionizing glaucoma treatment.
Commercialization and Expansion
Following FDA approval, Glaukos launched the iStent in the U.S. in July 2012 and secured 100% Medicare coverage in 2013. The company expanded internationally, launching iStent inject in Germany in 2014, further solidifying its Glaukos company milestones and achievements.
Financial Growth and Market Impact
The Glaukos company IPO in June 2015 raised approximately $108 million. By the first quarter of 2025, consolidated net sales reached $106.7 million, a 25% increase year-over-year, with U.S. glaucoma net sales up 41%. This growth highlights the company's significant impact on glaucoma treatment and its evolving business model.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
What are the key Milestones in Glaukos history?
The Glaukos company history is marked by significant advancements in ophthalmology, particularly in the development of minimally invasive glaucoma surgery (MIGS). The company's journey reflects a commitment to innovation, expanding its reach into corneal health and retinal diseases, while navigating the complexities of market access and financial performance.
| Year | Milestone |
|---|---|
| 2012 | Received FDA approval for the iStent Trabecular Micro-Bypass, the first ab interno glaucoma implant in the U.S. |
| 2019 | Acquired Avedro, establishing a corneal health franchise, and DOSE Medical to build a retinal R&D program. |
| 2020 | Launched the iStent inject W. |
| 2022 | Secured FDA 510(k) clearance for the iStent infinite Trabecular Micro-Bypass System for standalone use in refractory glaucoma. |
| 2023 | Received FDA approval for the iDose TR (travoprost intracameral implant) 75 mcg. |
| 2024 | Began initial commercial launch activities for iDose TR in the first quarter. |
Glaukos has consistently pushed the boundaries of ophthalmic treatment through groundbreaking innovations. The company's pioneering work in MIGS, starting with the iStent, revolutionized glaucoma care by offering less invasive surgical options. The development of the iDose TR represents a significant leap forward, providing a long-duration intracameral implant for continuous drug delivery, addressing a key challenge in patient adherence to topical medications.
iStent Trabecular Micro-Bypass
The first FDA-approved ab interno glaucoma implant, this 1mm titanium device enhances aqueous outflow, marking a new era in glaucoma treatment.
iStent inject
A second-generation device, even smaller at 0.23 mm x 0.36 mm, allowing for the injection of two stents through a single corneal entry.
Corneal Cross-Linking (iLink)
Following the acquisition of Avedro, Glaukos introduced the iLink procedure for treating keratoconus, expanding its corneal health franchise.
iDose TR (Travoprost Intracameral Implant)
This first-of-its-kind implant continuously delivers travoprost for extended periods, offering a solution for patient non-compliance with eye drops.
iStent infinite
Received FDA clearance for standalone use in patients with refractory glaucoma, broadening the application of their MIGS technology.
Retinal R&D Program
Established through the acquisition of DOSE Medical, this initiative signifies the company's strategic expansion into retinal diseases.
Despite its successes, Glaukos faces ongoing challenges in the competitive ophthalmology market. Securing broad market access and favorable reimbursement for its innovative therapies, such as the iDose TR with a wholesale acquisition cost of $13,950 per dose, remains a key focus. The company reported a net loss of $146.4 million in fiscal year 2024, an increase from the previous year, highlighting the financial demands of research, development, and market penetration.
Market Access and Reimbursement
Efforts are ongoing to expand coverage for iDose TR among Medicare Advantage and commercial payers. The gradual rollout of specialty pharmacy distribution is also part of this strategy.
Financial Performance
The company reported a net loss of $146.4 million in fiscal year 2024, which widened by 8.7% from 2023. This underscores the investment required for innovation and market expansion.
Competitive Landscape
The ophthalmology sector is highly dynamic, requiring continuous adaptation and strategic positioning to maintain leadership and secure market share.
Product Launch and Adoption
Successfully launching and driving adoption for novel technologies like iDose TR requires significant commercialization efforts and physician education.
Regulatory Environment
Navigating the regulatory pathways for new medical devices and pharmaceuticals is a continuous challenge, demanding rigorous data and adherence to standards.
Portfolio Diversification
While expanding into new areas like corneal health and retinal diseases is a strategic advantage, it also presents challenges in managing diverse product pipelines and market dynamics.
Glaukos Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What is the Timeline of Key Events for Glaukos?
The Glaukos company history traces a path of innovation in ophthalmic treatments, beginning with its founding in 1998. The Glaukos corporation timeline highlights a consistent focus on developing novel solutions for chronic eye diseases, starting with its early work on glaucoma stents.
| Year | Key Event |
|---|---|
| 1998 | Glaukos Corporation was founded in San Clemente, California, marking the Glaukos company founding. |
| 1999 | The first trabecular micro-bypass glaucoma stent was developed, a key step in the Glaukos iStent history. |
| 2001 | The first human implant of the micro-bypass glaucoma stent was performed. |
| 2002 | Initial venture capital funding, Series A, was secured, led by Versant Ventures. |
| 2005 | A landmark trial evaluating the iStent in conjunction with cataract surgery began. |
| 2012 | The FDA approved the iStent Trabecular Micro-Bypass, the first ab interno glaucoma implant approved in the U.S., and Glaukos launched it commercially. |
| 2013 | Glaukos secured 100% Medicare coverage for the iStent procedure. |
| 2015 | Glaukos completed its Initial Public Offering (IPO), a significant milestone in the Glaukos company stock history overview. |
| 2018 | The FDA approved iStent inject, a second-generation MIGS device. |
| 2019 | Glaukos acquired Avedro, establishing a corneal health franchise, and DOSE Medical for a retinal R&D program, showcasing Glaukos company acquisitions and partnerships. |
| 2020 | The iStent inject W was launched. |
| 2022 | The FDA granted 510(k) clearance for the iStent infinite Trabecular Micro-Bypass System for standalone use, a key part of Glaukos company regulatory approvals history. |
| 2023 | The FDA approved iDose TR (travoprost intracameral implant), a novel glaucoma treatment. |
| Q1 2024 | Initial commercial launch activities for iDose TR commenced in the U.S.. |
| 2024 | Full-year net sales reached $383.5 million, a 22% increase from 2023, reflecting strong performance. |
Continued Growth Driven by Innovation
Glaukos is set for continued expansion, fueled by its innovative product pipeline and growing market presence. The company's strategy is deeply rooted in its founding vision to transform vision care through novel, dropless platforms.
2025 Sales Guidance and iDose TR Adoption
The company reaffirmed its full-year 2025 net sales guidance between $475 million and $485 million. Strong adoption of iDose TR is anticipated as a primary growth catalyst.
Reimbursement Expansion and Financial Strength
Glaukos is actively working to broaden reimbursement coverage for iDose TR with Medicare Advantage and commercial payers. The company ended Q1 2025 with over $303 million in cash and equivalents and no debt, providing a robust financial position.
Advancing Product Pipeline and Future Prospects
The company's pipeline includes the NDA acceptance for Epioxa, a keratoconus treatment, with a PDUFA date of October 20, 2025. Analysts foresee iDose TR's launch as a transformative event for Glaukos' growth and profitability, especially from 2025 onwards. Understanding the Marketing Strategy of Glaukos is key to appreciating its market penetration. Glaukos company milestones and achievements underscore its impact on glaucoma treatment.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Competitive Landscape of Glaukos Company?
- What is Growth Strategy and Future Prospects of Glaukos Company?
- How Does Glaukos Company Work?
- What is Sales and Marketing Strategy of Glaukos Company?
- What are Mission Vision & Core Values of Glaukos Company?
- Who Owns Glaukos Company?
- What is Customer Demographics and Target Market of Glaukos Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.